1. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–35.
2. Clinical study report: a randomized, placebo-controlled, parallel-groups, outpatient study to compare the efficacy and safety of mk–0462 5 mg and sumatriptan 50 mg for the acute treatment of migraine (Protocol 029). https://classic.clinicaltrials.gov/ct2/show/NCT00897104 Accessed 12 May 2024.
3. Clinical study report: a randomized, placebo-controlled, parallel-groups, outpatient study to examine the safety, tolerability, and efficacy of single oral doses of MK–0462 5 mg, MK–0462 10 mg, and sumatriptan 100 mg for acute treatment of migraine protocol 030). https://classic.clinicaltrials.gov/ct2/show/NCT00898677. Accessed 12 May 12 2024.
4. Goldstein J, Ryan R, Jiang K et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998;38:737–747
5. Diener H-C, Förderreuther S, Kropp P et al (2018) Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie. Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien. Accessed 12 May 2024.